Beam Therapeutics Inc. (BEAM) Fundamental Analysis: Bull vs. Bear Case

BEAM

Beam Therapeutics Inc.

Fundamental data last updated:June 19, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/04/2026

Business Summary

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

VALUATION

P/E

-52.08

Market Cap ($M USD)

$3.37B

Forward P/E

-103.94

PEG

-2.08

PRICE TO SALES

20.57 PRICE TO BOOK

2.91 EV / EBITDA

-53.15

5-Year Average P/E

Free Cash Flow Yield

-11.38%

DCF Value

$-36.01

Graham Number

N/A

Price to FCF

-8.79

EV to FCF

-8.69

Earnings Yield

-1.92%

FCF Yield

-11.38%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.63

Next Year EPS Growth Estimate

-$0.32

Next Year Revenue Growth Estimate

$90.74B

Return on Equity (ROE)

-5.89%

FREE CASH FLOW

Operating Margin

-226.58%

Debt-to-Equity

0.24 Piotroski F-Score

3 Altman Z-Score

5.47 Return on Invested Capital (ROIC)

-26.43%

Current Ratio

16.99 Quick Ratio

16.99 Net Debt to EBITDA

0.60 Interest Coverage

-34.93

Gross Profit margin

-32.43%

FCF PER SHARE

$-3.72

REVENUE PER SHARE

$1.59

Gainseekers Quantitative Analysis

Summary

Beam Therapeutics Inc. is a perplexing case of market optimism clashing with financial reality. Recent pricing indicated it traded below its DCF value, suggesting potential undervaluation. However, the Forward P/E of -106.55 and a negative Earnings Yield highlight a company struggling to generate profits. The Altman Z-score of 5.53 suggests financial stability, yet the negative ROIC of -26.43% raises questions about management’s ability to create value. This stock is a high-risk, high-reward play, with the market seemingly betting on a turnaround.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, Beam Therapeutics is well-positioned to leverage AI and modern tech advancements. The company's focus on gene editing aligns with cutting-edge technological shifts, potentially enhancing its research and development capabilities. This positioning could enable Beam to innovate faster and more efficiently than its peers.

The Bull Case

For the bold investor, Beam's appeal lies in its potential for explosive growth. Despite a negative FCF Yield, the company's high Current Ratio of 16.99 and a Piotroski F-Score of 3 indicate a solid liquidity position. The staggering projected sales growth of over 90 billion percent next year suggests untapped pricing power and market demand. These factors could translate into significant capital efficiency if management executes effectively.

The Bear Case

Beam's structural weaknesses are glaring, with a Price/Sales ratio of 20.27 and a Price/Book of 2.87 indicating a potentially overvalued stock. The negative Operating Margin of -226.58% and Gross Profit Margin of -35.84% reveal deep operational inefficiencies. Additionally, the stock's proximity to its 52-week high raises concerns about technical overextension. These metrics suggest that Beam may struggle to justify its current valuation without substantial improvements.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$48.00

Institutional Ownership %

1-Year Beta

2.26 Insider Buying % (6 Mo)

Distance to 52-Week High

11.10%

Distance to 52-Week Low

53.20%

EARNINGS SURPRISE %

-4.60%

50-DAY SMA

$28.17

200-DAY SMA

$25.94

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.